FDA Antiviral Advisory Committee Recommends Approval For Investigational Protease Inhibitor Reyataz (Atazanavir)
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Antiviral Advisory Committee Recommends Approval For Investigational Protease Inhibitor Reyataz (Atazanavir)

PRINCETON, NJ -- May 14, 2003 -- Bristol-Myers Squibb Company (NYSE: BMY) is pleased that the U.S. Food and Drug Administration's (FDA) Antiviral Drug Advisory Committee unanimously recommended to the FDA that it approve the investigational protease inhibitor atazanavir (tradename Reyataz™) for the treatment of HIV-1 infection. While the FDA is not bound by the committee's recommendation, in most cases, the FDA will follow these recommendations.

Reyataz is currently undergoing review at the FDA. Bristol-Myers Squibb will continue to enroll patients in an Early Access Program (EAP), which allows eligible patients infected with HIV to receive atazanavir prior to its approval by the FDA. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

SOURCE: Bristol-Myers Squibb Company

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities